153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
JC Goh, Michael Millward(The University of Western Australia), Hui Gan(Ludwig Cancer Research), C. Fei(BeiGene (China)), I. Pires Da Silva(Westmead Hospital), Jermaine Coward(Royal Marsden NHS Foundation Trust), Amy Body(Monash Health), Bo Gao(Blacktown & Mount Druitt Hospital), Xinyu Li(BeiGene (China)), Lu Yang(Suizhou Central Hospital), Jiahang Sun(Harbin Medical University), Daphne Day(Monash Medical Centre), Mark Voskoboynik(Monash University)
Cited by 3
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
The epidermal growth factor receptor variant <scp>III</scp> (<scp>EGFR</scp>v<scp>III</scp>): where wild things are altered
|FEBS Journal|2013|357
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208